{"filings":[{"id":2078998,"accession_number":"0001140361-26-031423","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-08-05T20:10:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Q2 2026 net income $37.8M (+11% YoY); ASCENIV revenue $102.9M (+24% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $124.4M (+2% YoY); GAAP net income $37.8M (+11% YoY); GAAP basic EPS $0.17 (+17% YoY).","ASCENIV revenue $102.9M (+24% YoY); BIVIGAM revenue $19.4M (-49% YoY but sequential improvement from Q1 2026 trough).","Gross margin expanded to 69% from 55% YoY, driven by product mix shift toward higher-margin ASCENIV and yield-enhanced manufacturing.","Adjusted EBITDA $61.8M (+22% YoY); FY2026 guidance reiterated: revenue $530-560M, adj. EBITDA $265-300M.","Repurchased ~7.1M shares in Q2 (13.8M YTD, 5.3% of shares outstanding); SG-001 development on track for pre-IND submission by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805840,"accession_number":"0001140361-26-023705","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-06-02T20:05:29+00:00","items":["5.07"],"status":"ready","headline":"ADMA Biologics annual meeting results: all proposals pass including election of two Class I directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Alison C. Finger elected as Class I director with 156.8M for, 19.4M withheld, 23.0M broker non-votes.","Eduardo Rene Salas elected with 172.0M for, 4.3M withheld, 23.0M broker non-votes.","Ratification of KPMG as auditor for FY2026 approved: 198.7M for, 0.33M against, 0.28M abstain.","Non-binding Say-on-Pay proposal approved with 168.2M for, 7.7M against, 0.33M abstain, 23.0M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92449,"accession_number":"0001140361-26-019295","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Q1 revenue flat at $114.5M, ASCENIV up 28%; withdraws long-term guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $114.5M flat YoY; ASCENIV rev $97.5M (+28%) offset by BIVIGAM -54%.","GAAP net income $45.3M (+68%); Adjusted net income $40.7M (+22%); Adjusted EBITDA $59.7M (+24%).","FY 2026 guidance: rev $530-560M, Adj EBITDA $265-300M; withdraws long-term guidance due to market dynamics.","Audit committee review found no improper channel stuffing or undisclosed related-party transactions.","Cash from ops $58M; gross margin expanded to 71% from 53% on product mix shift."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":114493000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92448,"accession_number":"0001140361-26-018667","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics receives FDA approval to expand ASCENIV label to pediatric patients 2 years+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved label expansion for ASCENIV to include pediatric primary humoral immunodeficiency patients aged 2 years and older.","Previously approved only for patients 12 years and older; approval fulfills post-marketing pediatric assessment commitment.","CEO Adam Grossman: expanded label allows addressing treatment needs of younger PI patients earlier in their treatment journey.","COO Kaitlin Kestenberg highlighted collaboration with PI community and families; approval reflects strong clinical execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103293,"accession_number":"0001140361-26-011569","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics refutes Culper Research short seller allegations; provides inventory & demand data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Demand for ASCENIV growing; end-user demand increased past two years; current days on hand average 90 days as of March 22, 2026.","Refutes channel stuffing; says distributor inventory levels consistent with industry standards; average days on hand above safety stock: 48 days for ASCENIV, 51 days for BIVIGAM as of March 22.","ASCENIV positioned as late-line therapy for immune compromised patients who fail standard IG; premium pricing; new IVIG launches not competitive threat.","ADMA received unqualified audit opinions from Big Four firm for FY2024 and FY2025; prior auditor resigned due to acquisition.","No undisclosed related party transactions; no Grossman-family entity distributed or took title to any ADMA products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103292,"accession_number":"0001140361-26-007230","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.","Total 2026 share repurchase initiative target is ~$200M, funded via existing $225M revolving credit facility.","Since program authorization in May 2025, ~$160M of common stock repurchased to date.","CEO states stock is \"meaningfully undervalued\" relative to business strength and growth trajectory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103291,"accession_number":"0001140361-26-006781","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"ADMA Biologics reports record FY2025 revenue $510M (+20%), Adj. EBITDA $231M (+40%); CFO transition to Kohler","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $510.2M (+20% YoY); ASCENIV revenue $363M (+51% YoY). Gross margin 57.4% vs 51.5%.","GAAP net income $146.9M (FY2024: $197.7M incl. $84.3M tax benefit). Adjusted net income $160.8M (+35% YoY). Adjusted EBITDA $231M (+40%).","FY2026 guidance: revenue >$635M, Adj. net income >$255M, Adj. EBITDA >$360M. Targeting >$1.1B revenue by FY2029.","CFO Brad Tade retiring effective Feb 25, 2026; succeeded by Terry Kohler (ex-CFO of OptiNose, Verrica). Kohler will become CFO/Treasurer Feb 26.","Q4 2025: revenue $139.2M (+18% YoY); GAAP net income $49.4M; Adj. EBITDA $73.6M (+52% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":510173000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103290,"accession_number":"0001140361-26-000906","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADMA prelim FY2025 rev ~$510-511M, raises FY2026 rev/EBITDA guidance, targets >$1.1B by 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 total revenue ~$510-511M, meeting or exceeding prior guidance. Cash grew to ~$88M with ~$40M Q4 operating cash flow.","FY2026 revenue guidance raised to ~$635M (from $630M); FY2026 adjusted EBITDA raised to ~$360M (from $355M). Adjusted net income reiterated at ~$255M.","FY2027 revenue guided ~$775M, adjusted net income ~$315M, adjusted EBITDA ~$455M.","Long-term targets: >$1.1B revenue and >$700M adjusted EBITDA by FY2029. Yield-enhanced production now routine, 2026 first full year of monetization.","Divested three plasma centers for $12M, secured long-term supply agreements, expects accretive cost savings from strategic repositioning."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":510173000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119545,"accession_number":"0001140361-25-040539","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).","Revenue guidance raised: FY25 to ≥$510M (from >$500M); FY26 to ≥$630M (from >$625M).","Adj EBITDA guidance: FY25 reaffirmed at $235M; FY26 raised to >$355M (from >$340M).","FDA lot release of first yield-enhanced batches; gross margin expansion expected from Q4 2025.","Record ASCENIV demand; real-world data shows >50% infection reduction (2.1→0.9/year)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":371010000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136113,"accession_number":"0001140361-25-029143","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","9.01"],"status":"ready","headline":"ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).","GAAP net income $34.2M; Adjusted EBITDA $50.8M, up 59% YoY underlying.","Began commercial-scale yield-enhanced IG manufacturing delivering 20%+ output gain.","Closed $300M J.P. Morgan-led financing ($75M term loan, $225M revolver) replacing Ares debt.","Reaffirmed FY2025-2026 guidance; pre-2030 revenue target $1.1B+; repurchased $15M stock."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":236786000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153161,"accession_number":"0001140361-25-021440","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ADMA Biologics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jerrold B. Grossman elected with 165.1M votes for, 16.5M withheld; 23.4M broker non-votes.","Lawrence P. Guiheen elected with 133.8M for, 47.8M withheld; 23.4M broker non-votes.","Ratification of KPMG as auditor: 204.6M for, 269,649 against, 127,057 abstain.","Non-binding say-on-pay approved: 161.5M for, 19.9M against, 266,852 abstain; 23.4M broker non-votes.","Shareholders favored 1-year frequency for future say-on-pay votes (173.1M votes for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153160,"accession_number":"0001140361-25-017704","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).","FY2025 revenue guidance raised to >$500M; FY2026 to >$625M; adjusted EBITDA guidance >$235M and >$340M, respectively.","Board authorized $500M share repurchase program (~8% of market cap); timing and amount discretionary.","Debt reorganized: $30M borrowed on revolver to repay term loan; revolver outstanding $72.5M, term loan $2.5M; cost of debt down 1.1%.","FDA-approved yield enhancement process expected to increase IG output 20% from same plasma volume, supporting future growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":114802000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153159,"accession_number":"0001140361-25-015881","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics receives FDA approval for yield enhancement process; expects ~20% output increase","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved innovative production yield enhancement process increasing yields by ~20% from same plasma volume.","Approval applies to both immune globulin products ASCENIV and BIVIGAM.","CEO anticipates revenue and earnings acceleration beginning late 2025 and accelerating into 2026.","First U.S. regulatory approval for such a process; highlights ADMA's internal R&D and capital efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171945,"accession_number":"0001140361-25-006745","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).","Q4 2024 revenue $117.5M (+59% YoY); GAAP net income $111.9M vs net loss of $17.6M; Adjusted EBITDA $48.3M vs $18.6M.","FY 2025 revenue guidance raised to >$490M; FY 2026 >$605M; expects >$1B total revenue before 2030.","FDA approval of yield enhancement process expected mid-2025, potentially increasing IG yields ~20%; long-term plasma supply from ~250 centers.","Form 10-K filing delayed to on or before March 18, 2025 due to need for additional time to test internal controls with KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171944,"accession_number":"0001140361-25-005489","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics sets 2025 executive comp; CEO Grossman base $925k with equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Grossman: 2025 base $925k, 2024 cash bonus $1.02M, 252,022 RSUs, 376,744 options at $16.07 strike.","COO Kestenberg: 2025 base $575k, 2024 bonus $293,625, 77,784 RSUs, 116,279 options.","CFO Tade: 2025 base $500k, 2024 bonus $254,475, 62,227 RSUs, 93,023 options.","Non-employee directors get annual equity grants of $350k (50% RSUs, 50% options) and increased committee retainers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171943,"accession_number":"0001140361-25-000871","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics furnishes January 2025 corporate presentation without material updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation furnished under Regulation FD; no specific financial results or guidance changes disclosed.","Presentation expected to be used in meetings with investors, analysts, and strategic partners.","Exhibit contains only a title slide; no operational or strategic updates provided.","Company makes no admission as to materiality of information furnished."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171942,"accession_number":"0001140361-25-000870","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.","FY2025 revenue guided >$485M, net income >$170M, Adj EBITDA >$220M; FY2026 revenue >$600M, net income >$230M.","PAS submitted to FDA for yield enhancement process that could increase IG yields ~20%; approval expected mid-2025.","Executed long-term high titer plasma supply contracts from ~250 collection centers (5x increase) to support ASCENIV growth.","Balance sheet: net cash surplus vs. $75M debt; expect >$1B annual revenue before 2030 with outsized earnings growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":426454000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171941,"accession_number":"0001140361-25-000073","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics appoints Eduardo Rene Salas to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Eduardo Rene Salas as Class I director, term expiring at 2026 annual meeting.","Salas is former EY audit partner (2002-2019) and former CFO of Wellstat Therapeutics (2020-2022).","He currently serves on audit committee of Intra-Cellular Therapies (since 2022).","He will receive initial grant of options to purchase 20,011 shares of common stock.","No material transactions or arrangements in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188943,"accession_number":"0001140361-24-050002","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics repays $30M of senior secured term loan, total debt reduced to $75M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $30M of original $62.5M term loan with Ares Capital using cash on hand.","Total gross debt now $75M: $42.5M revolver plus $32.5M term loan outstanding.","This is second paydown in four months; total gross debt reduced by 29%.","Lowered interest expense expected to enhance near-term earnings growth potential.","CEO cites confidence in sustained earnings growth and ongoing cash generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188942,"accession_number":"0001140361-24-047487","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics board member Bryant Fong resigns; committee chairs reassigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryant Fong resigned from board effective Nov 19, 2024 to focus on other roles; no disagreements.","Young T. Kwon appointed Chairman of Audit Committee and designated audit committee financial expert.","Steven A. Elms added to Audit Committee.","Alison C. Finger added to Governance and Nominations Committee and Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188941,"accession_number":"0001140361-24-045657","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q3 total revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%); Adj. EBITDA $45.4M (+256%)","FY2024 guidance raised: revenue >$415M (from >$400M), GAAP net income >$120M (from >$105M), Adj. EBITDA >$160M (from >$150M)","FY2025 guidance raised: revenue >$465M, net income >$165M, Adj. EBITDA >$215M","Appointed KPMG as new independent registered public accounting firm, replacing CohnReznick after 17 years","ASCENIV now >50% of revenue; sBLA filing planned for label expansion; pediatric study database lock in Q4 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":308905000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188940,"accession_number":"0001140361-24-044808","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ADMA Biologics engages KPMG as new auditor effective after Q3 2024 10-Q filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KPMG appointed as independent registered public accounting firm on October 31, 2024, effective upon filing of Q3 2024 10-Q.","No consultations or disagreements with KPMG during prior fiscal years 2022-2023 and interim period through October 31, 2024.","KPMG will audit the consolidated financial statements for FY 2024, expected to be filed by March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188939,"accession_number":"0001140361-24-043250","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics affirms 2024-2025 guidance unaffected by auditor switch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Management stated no anticipated impact to previously provided 2024-2025 financial guidance from auditor transition.","Statement made after market close on Oct 9, 2024, in discussions with analysts.","Auditor change described in separate Form 8-K filed on Oct 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188938,"accession_number":"0001140361-24-043222","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ADMA Biologics auditor CohnReznick resigning effective after Q3 2024 filing; audit committee seeking replacement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CohnReznick LLP notified ADMA of resignation as independent auditor effective after filing of Q3 2024 10-Q.","No disagreements or reportable events during fiscal years 2022 and 2023 or subsequent interim period.","Audit Committee initiated process to select new auditor for FY 2024 audit and internal control over financial reporting.","CohnReznick's reports on FY 2023 and 2022 financials were unqualified, no adverse opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205415,"accession_number":"0001140361-24-037184","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA repays $30M of revolver; total debt reduced to $105M, a 22% reduction","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $30M from $72.5M Ares Capital revolver with no prepayment penalties.","Total gross debt reduced to $105M ($62.5M term loan + $42.5M revolver).","Paydown funded from cash on hand generated organically.","Lower interest expense expected to enhance earnings growth.","Company expects further reduction and optimization of capital costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205414,"accession_number":"0001140361-24-036399","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.","Adjusted EBITDA $44.5M, up ~592% YoY; gross margin improved to 53.6% from 27.8%.","FY2024 revenue guidance raised to >$400M (from >$355M); FY2025 revenue >$445M (from >$410M).","FY2024 GAAP net income guidance raised to >$105M; adjusted EBITDA guidance >$150M.","Commercial-scale yield enhancement of ~20% from same starting plasma; potential benefit as early as Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":189066000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205413,"accession_number":"0001140361-24-034440","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics promotes Brad Tade to CFO and Treasurer, effective July 24, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Tade, former VP Financial Operations, promoted to CFO and Treasurer effective July 24, 2024.","Base salary set at $435,000 annually; target bonus of 45% of base salary.","Granted 115,100 stock options and 72,400 RSUs, each vesting over four years.","Severance includes 12 months base salary; 15 months plus 1.5x target bonus if within one year of change of control.","Tade joined ADMA in June 2023; prior roles at Baxter International and Becton Dickinson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222324,"accession_number":"0001140361-24-031778","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ADMA Biologics amends bylaws to reduce director removal threshold to majority vote and add exclusive forum provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced director removal with cause threshold from 66 2/3% to a majority of voting holders.","Added exclusive forum provision requiring internal corporate suits be brought in Delaware courts.","Added federal forum selection clause for Securities Act claims unless company consents otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222323,"accession_number":"0001140361-24-028800","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADMA Biologics shareholders elect three Class II directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Steven A. Elms, Adam S. Grossman, Young T. Kwon elected as Class II directors with 71%, 97%, 98% of votes cast excluding broker non-votes.","Ratification of CohnReznick LLP as independent auditor for FY2024 approved with 184.5M for, 2.0M against, 0.2M abstain.","Annual meeting quorum achieved with 186.7M shares represented out of 231.8M outstanding (80.5% of shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222322,"accession_number":"0001140361-24-026601","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics posts May 2024 corporate presentation; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation titled 'Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology' made available.","Presentation intended for use in discussions with potential investors, strategic partners, and analysts.","No new financial guidance, product milestones, or material operational changes were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222321,"accession_number":"0001140361-24-025173","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q1 revenue $81.9M (+44% YoY); raises FY2024-25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $17.8M vs net loss of $6.8M in prior year; adjusted EBITDA $26.4M, a 970% increase.","Gross margin improved to 48% from 29% YoY; working capital $223.3M, cash $45.3M.","FY2024 revenue guidance raised to >$355M (prior >$330M); net income >$85M (prior >$65M).","FY2025 revenue guidance raised to >$410M; adjusted EBITDA >$160M, up from >$140M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":81875000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222320,"accession_number":"0001140361-24-017331","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics promotes Kaitlin Kestenberg to COO and SVP, Compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kestenberg promoted from SVP, Compliance & Project Operations to COO and SVP, Compliance, effective April 1, 2024.","Base salary of $460,000; annual target bonus of 50% of base salary.","Granted options for 300,328 shares and 192,320 RSUs, each vesting over four years.","Severance includes 12 months salary (or 15 months plus 1.5x bonus upon change of control) plus COBRA.","Kestenberg has been with ADMA since 2011; prior roles at Acorda Therapeutics and Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241847,"accession_number":"0001140361-24-012605","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves extended room temperature storage for ADMA's ASCENIV and BIVIGAM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved supplemental BLAs to allow 4-week room temperature (25°C) storage at any time during the 36-month shelf life.","Previously, room temperature storage was only allowed during the first 24 months; now applies to all existing and future lots.","CEO Adam Grossman stated the approval enables reaching customers previously limited by cold chain constraints.","Both products are immediately commercially available to U.S. healthcare providers.","Approval expected to improve inventory management and product administration for providers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241846,"accession_number":"0001140361-24-011399","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics furnishes corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Regulation FD; presentation intended for investor and analyst meetings.","Presentation content not summarized; no financial results or material updates provided.","Company undertakes no duty to update the information in the filing.","Presentation available on company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241845,"accession_number":"0001140361-24-010100","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ADMA Biologics CFO Brian Lenz steps down; CEO Grossman named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Brian Lenz transitions to consulting role effective April 1, 2024; consulting agreement through March 31, 2025.","CEO Adam Grossman appointed Interim CFO; executive search initiated for permanent replacement.","Grossman's 2024 base salary set at $800,000; awarded 557,728 RSUs and options for 870,950 shares at $5.40.","Lenz receives $334,875 cash bonus for 2023 performance (141% of corporate goals achieved)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241844,"accession_number":"0001140361-24-010088","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q4 rev $73.9M (+48%); FY rev $258.2M; raises FY24/25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 total revenue $73.9M, up 48% YoY; FY 2023 total revenue $258.2M, up 68% YoY.","Q4 adjusted net income $8.5M (vs loss $12.2M); FY adjusted net income $0.7M (vs loss $59.2M).","FY 2024 guidance raised: revenue >$330M, net income >$65M, adjusted EBITDA >$90M.","FY 2025 guidance raised: revenue >$380M, net income >$115M, adjusted EBITDA >$140M.","Pipeline: S. pneumonia hyperimmune globulin potential peak rev $300-500M; ASCENIV pediatric study ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":258215000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241843,"accession_number":"0001140361-24-008680","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics launches AI program ADMAlytics, automates plasma pooling in first commercial batch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADMAlytics combines generative AI and machine learning to optimize production processes.","First successful commercial use: automated plasma pooling for ASCENIV production.","Broader implementation across supply chain and operations expected to yield efficiencies.","CEO Adam Grossman says ADMAlytics supports earnings growth trajectory and continuity of patient care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241842,"accession_number":"0001140361-24-001198","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics furnishes January 2024 corporate presentation; no specific financial or operational updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing furnishes a corporate presentation under Item 7.01 Regulation FD.","Presentation titled 'Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology'.","No earnings, guidance, or material business developments provided in the exhibit.","Presentation is available on ADMA's website under Investors section."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241841,"accession_number":"0001140361-24-001194","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA raises FY2024-25 revenue guidance; preliminary Q4 rev $72-74M, FY rev $256-258M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 preliminary revenue $72-74M; full year $256-258M.","FY2024 revenue guidance raised to >$320M from $290M; FY2025 to >$370M from $335M.","FY2024 net income expected >$60M (from $55M) and adjusted EBITDA ~$85M.","New growth: manufacturing yield enhancement and S. pneumonia hyperimmune globulin (potential peak revenue $300-500M).","ASCENIV label expansion via pediatric study progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":258215000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259290,"accession_number":"0001140361-23-058160","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["1.01","1.02","2.03","8.01","9.01"],"status":"ready","headline":"ADMA Biologics refinances with $135M Ares facility, repays $159M Hayfin debt, reduces debt 15%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $135M senior secured credit facility ($72.5M revolver + $62.5M term loan) fully drawn to repay prior Hayfin debt.","Total debt reduced 15% from $159M to $135M; 4-year interest-only maturity (Dec 2027).","Term loan initial rate SOFR+6.50% (11.88%); revolver initial rate SOFR+3.75% (9.13%), lower than prior facility.","Proceeds used to terminate Hayfin credit facility; cash on hand contributed to payoff.","CEO states transaction is non-dilutive and supports earnings growth; Ares Management credit funds provide financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259289,"accession_number":"0001140361-23-057341","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves ADMA's BIVIGAM for pediatric PI patients aged 2 and older","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved supplemental BLA for BIVIGAM to treat primary humoral immunodeficiency (PI) in patients 2 years and older.","Prior indication restricted to PI patients aged 12 years and older; label expansion opens new pediatric segment.","Approval fulfills post-marketing commitment from original BLA; final pediatric study report completed.","CEO Adam Grossman stated expanded label allows treating younger PI patients earlier in their treatment journey.","ADMA will offer BIVIGAM as an FDA-approved option for pediatric PI patients aged 2+ immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259288,"accession_number":"0001140361-23-053665","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA receives FDA approval for 10th plasma collection center; achieves plasma supply self-sufficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval for Laurel, MD facility (10th ADMA BioCenters center) to introduce source plasma into interstate commerce.","Facility began operations and collection in H1 2023; now licensed for further manufacturing in the U.S.","Management says approval accomplishes goal of plasma self-sufficiency, supporting revenue growth and profitability outlook.","Center uses Haemonetics NexSys Persona® collection system; expects ~50 staff at full capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259287,"accession_number":"0001140361-23-052102","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q3 2023: first-time net income $2.6M, revenue $67.3M (+64% YoY), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $67.3M, up 64% YoY; first-time positive GAAP net income of $2.6M (vs $14.9M loss YoY).","Adjusted EBITDA grew to $12.7M, up 98% QoQ; first-time positive operating cash flow of $12.0M; cash balance $74.2M.","Gross margin improved to 36.6% from 23.5% YoY; net leverage ratio improved to 1.6x.","FY2023 revenue guidance raised to >$250M; FY2024 >$290M; FY2025 >$335M (from $240M, $275M, $320M previously).","Targets consolidated gross margin 40-50% and net income margin 20-30% in 2024-2025; ongoing strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":184311323.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259286,"accession_number":"0001140361-23-046335","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics appoints Alison C. Finger to board as Class I director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alison C. Finger appointed to board effective Sept 28, 2023; term expires at 2026 annual meeting.","Ms. Finger was Chief Commercial Officer at bluebird bio (Aug 2015-Jan 2021) and held VP roles at BMS.","Initial grant of options to purchase 98,870 shares of common stock upon joining the board.","No arrangements or transactions requiring disclosure under Item 404(a) exist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276554,"accession_number":"0001140361-23-038803","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics raises FY2023 revenue guidance to >$240M; Q2 revenue up 77% to $60.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 total revenues $60.1M (+77% YoY); gross margin 27.8% (vs. 22.9% Q2 2022); normalized margin 31-32% excl. IT disruption.","Adjusted EBITDA $6.4M vs. -$6.3M YoY; net loss narrowed to $6.4M from $13.8M; adjusted net loss $3.6M.","FY2023 revenue guidance raised to at least $240M (from $220M); FY2024 raised to $275M; FY2025 to $325M+.","Nonrecurring IT disruption charge of $2.8M in COGS; production has resumed; # of FDA-licensed plasma centers on track for 10 by year-end.","Terminated financial advisory agreement with Morgan Stanley; continues to evaluate strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":117036725.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276553,"accession_number":"0001140361-23-035123","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics receives FDA approval for ninth plasma collection center in Dallas, GA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Dallas, GA facility's BLA; center began plasma collection in Q3 2022.","Facility now licensed to collect and ship source plasma interstate for manufacturing.","Company on track to have all 10 centers FDA-licensed by year-end 2023.","Supports plasma self-sufficiency, revenue growth, and profitability outlook.","Facility features Haemonetics NexSys Persona system; expects staff of 50 at capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294311,"accession_number":"0001140361-23-028551","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADMA Biologics stockholders elect director and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bryant E. Fong elected Class I director with 104,032,764 votes for, 43,796,163 withheld, 31,645,337 broker non-votes.","Ratification of CohnReznick LLP as independent auditor for FY 2023: 178,835,482 for, 407,959 against, 230,823 abstain.","Quorum of 179,474,264 shares represented out of 222,249,295 outstanding as of April 10, 2023 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294310,"accession_number":"0001140361-23-025873","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics to fill Class I director vacancy by Dec 31, 2023 with candidate meeting Nasdaq diversity criteria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["After Annual Meeting and re-election of Bryant Fong, a Class I director vacancy will exist.","Board intends to fill vacancy with a candidate meeting Nasdaq gender diversity criteria.","Active search for candidate with diversity of skill, experience, gender, race, ethnicity, and age.","Company aims to fill the vacancy on or before December 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294309,"accession_number":"0001140361-23-023899","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q1 revenue $56.9M (+96% YoY); first-time positive Adjusted EBITDA $2.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $56.9M, up 96% YoY; net loss narrowed to $6.8M from $25.0M.","First-time positive Adjusted EBITDA of $2.5M, ahead of forecast; FY2023 revenue guidance raised to >$220M.","Gross margin improved to 29.0% from 12.6%; legacy low-margin BIVIGAM inventory nearly depleted.","ASCENIV production scaled to 4,400L; expects margin expansion and plant capacity improvement.","Cash $69.2M; working capital $227.4M; strategic review ongoing with Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":56913534.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294308,"accession_number":"0001140361-23-022312","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"ADMA Biologics amends Hayfin credit agreement, cuts rate by 1%, extends $25M delayed draw loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest rate reduced 1% to SOFR + 8.50%; up to 2.50% interest may be paid in kind.","New 50% waiver of prepayment fee on acquisition or strategic transactions within 24 months.","Delayed draw term loan of $25M extended from June 30, 2023 to December 31, 2023.","Issued warrants for 2,391,244 shares at $3.2619 per share, expiring May 1, 2030.","Total debt level unchanged; company cites strengthened financial outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-02T23:59:59+00:00|294308"}